Thomas Gruenberger

18.4k total citations · 5 hit papers
192 papers, 10.2k citations indexed

About

Thomas Gruenberger is a scholar working on Oncology, Hepatology and Surgery. According to data from OpenAlex, Thomas Gruenberger has authored 192 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Oncology, 126 papers in Hepatology and 67 papers in Surgery. Recurrent topics in Thomas Gruenberger's work include Hepatocellular Carcinoma Treatment and Prognosis (108 papers), Colorectal Cancer Treatments and Studies (90 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (38 papers). Thomas Gruenberger is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (108 papers), Colorectal Cancer Treatments and Studies (90 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (38 papers). Thomas Gruenberger collaborates with scholars based in Austria, Germany and United Kingdom. Thomas Gruenberger's co-authors include Werner Scheithauer, Dietmar Tamandl, Bernard Nordlinger, Wolf O. Bechstein, Birgit Gruenberger, Bengt Glimelius, Graeme J. Poston, Eric Van Cutsem, Halfdan Sørbye and Euan Walpole and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas Gruenberger

182 papers receiving 10.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

2008 1.4k citations Bernard Nordlinger, Bengt Glimelius et al. profile →
Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study

2009 1.2k citations Thomas Gruenberger et al. profile →
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

2013 853 citations Bernard Nordlinger, Bengt Glimelius et al. profile →
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

2009 671 citations Thomas Gruenberger, Wolf O. Bechstein et al. profile →
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2016 471 citations Juan W. Valle, Ivan Borbath et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Thomas Gruenberger

Since Specialization

Citations

This map shows the geographic impact of Thomas Gruenberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Gruenberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Gruenberger more than expected).

Fields of papers citing papers by Thomas Gruenberger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Gruenberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Gruenberger. The network helps show where Thomas Gruenberger may publish in the future.

Co-authorship network of co-authors of Thomas Gruenberger

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Gruenberger. A scholar is included among the top collaborators of Thomas Gruenberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Gruenberger. Thomas Gruenberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial 2024 ·Cancers ·(unknown), Jonas Santol, Birgit Gruenberger, A. Lenauer, Friedrich Laengle, Josef Thaler, (unknown), Wolfgang Eisterer, Angela Djanani, Judith Stift, Thomas Gruenberger	1
2	The blood microbiome and its impact on hepatic failure after liver surgery 2024 ·HPB ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Thomas Gruenberger, Alice Assinger, Nicholas Chia, (unknown)	1
3	Surgical management of liver metastasis from colorectal cancer 2023 ·memo - Magazine of European Medical Oncology ·(unknown), Thomas Gruenberger	0
4	Transcriptomic landscapes of effective and failed liver regeneration in humans 2023 ·JHEP Reports ·Patrick Starlinger, (unknown), (unknown), David Pereyra, Jonas Santol, (unknown), Matthias Hackl, Susanna Skalicky, Hubert Hackl, (unknown), Daniel R. O’Brien, Renate Kain, Petra Hirsova, Gregory J. Gores, Chen Wang, Thomas Gruenberger, Rory L. Smoot, Alice Assinger	8
5	Tyrosine phosphorylation of YAP‐1 in biliary epithelial cells mediates posthepatectomy liver regeneration and is affected by serotonin 2023 ·Journal of Cellular Biochemistry ·Patrick Starlinger, (unknown), (unknown), David Pereyra, Judith Stift, Michaela Finsterbusch, Jonas Santol, Thomas Gruenberger, Alice Assinger, Rory L. Smoot	1
6	The Effect of Induction Chemotherapy with VEGF Inhibition on Tumor Response in Synchronously Metastasized Potentially Resectable Colorectal Cancer 2023 ·Cancers ·(unknown), (unknown), Jan Philipp Jonas, (unknown), (unknown), (unknown), Mohamed E. Salem, Jonas Santol, (unknown), M. Klimpfinger, (unknown), Thomas Gruenberger	1
7	Effect of Goal-Directed Crystalloid versus Colloid Administration on Perioperative Hemostasis in Partial Hepatectomy: A Randomized, Controlled Trial 2021 ·Journal of Clinical Medicine ·Johannes Gratz, Oliver Zotti, (unknown), Marion Wiegele, Edith Fleischmann, Thomas Gruenberger, Claus G. Krenn, Barbara Kabon	3
8	Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases 2020 ·British Journal of Cancer ·Stefan Stremitzer, Peter Vermeulen, (unknown), Mark Kockx, Luc Dirix, Dongyun Yang, Wu Zhang, Judith Stift, Friedrich Wrba, Thomas Gruenberger, Heinz‐Josef Lenz, Stefan Scherer	31
9	Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection 2017 ·Hepatology ·Patrick Starlinger, David Pereyra, Stefanie Haegele, (unknown), (unknown), Florian Primavesi, Andreas Köhler, (unknown), Thomas Reiberger, Arnulf Ferlitsch, Barbara Meßner, Guido Beldi, Stefan Staettner, Christine Brostjan, Thomas Gruenberger	34
10	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection 2016 ·Molecular Cancer Therapeutics ·Stefan Stremitzer, Wu Zhang, Dongyun Yang, Yan Ning, Yu Sunakawa, Satoshi Matsusaka, (unknown), Satoshi Okazaki, Diana L. Hanna, Stephanie H. Astrow, (unknown), (unknown), Craig Stephens, Stefan Scherer, Judith Stift, Friedrich Wrba, Thomas Gruenberger, Heinz‐Josef Lenz	8
11	PARAGON II – A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer 2016 ·European Journal of Surgical Oncology ·Robert Jones, Hafiz Malik, Stephen W. Fenwick, Monica Terlizzo, Elizabeth O’Grady, Stefan Stremitzer, Thomas Gruenberger, M. Rees, G. Plant, Joan Figueras, (unknown), René Adam, (unknown), Graeme J. Poston	28
12	Perioperative Non-Invasive Indocyanine Green-Clearance Testing to Predict Postoperative Outcome after Liver Resection 2016 ·PLoS ONE ·Stefanie Haegele, (unknown), (unknown), (unknown), David Pereyra, Stefan Stremitzer, Edith Fleischmann, Christine Brostjan, Thomas Gruenberger, Patrick Starlinger	36
13	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up breakdown → 2016 ·Annals of Oncology ·Juan W. Valle, Ivan Borbath, Shahid A. Khan, F. Huguet, Thomas Gruenberger, Dirk Arnold	471
14	Randomised, Phase 2 Study (OLIVIA) of Bevacizumab Plus mFOLFOX6 or Folfoxiri in Patients with Initially Unresectable Colorectal Cancer Liver Metastases 2013 ·Annals of Oncology ·René Adam, John Bridgewater, Ian Chau, Pilar Alfonso, Michel Rivoire, S. Lasserre, Daniel Waterkamp, Thomas Gruenberger	3
15	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells 2009 ·Molecular Cancer Therapeutics ·Beata Herberger, Walter Berger, Harald Puhalla, Katharina Schmid, Sabine Novak, Anita Brandstetter, Christine Pirker, Thomas Gruenberger, Martin Filipits	26
16	Neoadjuvant Treatment of Colorectal Cancer with Bevacizumab: The Perioperative Angiogenic Balance Is Sensitive to Systemic Thrombospondin-1 Levels 2008 ·Clinical Cancer Research ·Christine Brostjan, (unknown), Birgit Gruenberger, (unknown), (unknown), (unknown), R. Roka, Thomas Gruenberger	25
17	Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. 2007 ·PubMed ·Harald Puhalla, Friedrich Wrba, Daniela Kandioler, (unknown), Anh Tuan Huynh, Thomas Gruenberger, Dietmar Tamandl, Martin Filipits	32
18	Survival after peri-operative chemotherapy with folfox 4 and surgery for resectable colorectal cancer liver metastases. Final results of the eortc intergroup randomized phase III study 40983 2007 ·Annals of Oncology ·Bernard Nordlinger, (unknown), Laurence Collette, Marleen Praet, Bengt Glimelius, (unknown), P. Schlag, P Rougier, Wolf O. Bechstein, John Primrose, Euan Walpole, Meg Finch-Jones, D Jaeck, D. Mirza, R.W. Parks, Thomas Gruenberger	1
19	Treatment and outcome of intrahepatic cholangiocellular carcinoma 2005 ·The American Journal of Surgery ·Harald Puhalla, B. Schuell, H. Pokorny, Gabriela Kornek, Werner Scheithauer, Thomas Gruenberger	56
20	Influence of donor criteria on postoperative graft function after orthotopic liver transplantation 1994 ·Transplant International ·Thomas Gruenberger, Rudolf Steininger, Thomas Sautner, Martina Mittlböck, Ferdinand Mühlbacher	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact